LY96 as A Cancer, Autoimmune and Inflammation Drug Target and Biomarker

Target Name: LY96

NCBI ID: G23643

LY96 as A Cancer, Autoimmune and Inflammation Drug Target and Biomarker

LY96 (Lymphocyte antigen 96) is a protein that is expressed in a variety of tissues, including the spleen, lymph nodes, and bone marrow. It is a type of cytokine that is produced by T-cells in response to the presence of foreign substances in the body. LY96 has also been identified as a potential drug target and biomarker for several diseases, including cancer, autoimmune disorders, and inflammation.

The discovery of LY96 as a potential drug target comes from a study by researchers at the University of California, San Diego School of Medicine. In this study, the researchers found that LY96 was expressed in the lymph nodes of individuals with various types of cancer, and that inhibiting the activity of LY96 was able to reduce the growth of these cancer cells. This suggests that LY96 may be a useful target for cancer treatments.

In addition to its potential use as a cancer treatment, LY96 has also been identified as a potential biomarker for several other diseases. For example, research has suggested that LY96 may be a useful biomarker for evaluating the effectiveness of anti-inflammatory treatments. In this context, LY96 may be used to assess the extent to which inflammation is being reduced in individuals with certain diseases.

Another potential application of LY96 as a biomarker is its use in the study of autoimmune disorders. LY96 has been shown to be involved in the development and progression of autoimmune diseases, and may be a useful target for therapies aimed at treating these conditions. For example, a study by researchers at the University of California, San Diego School of Medicine has shown that LY96 is involved in the development of rheumatoid arthritis, and that inhibiting its activity may be an effective way to treat this disease.

Finally, LY96 has also been identified as a potential target for the treatment of inflammation in general. In this context, LY96 may be used to treat a wide range of conditions that involve inflammation, such as allergies, asthma, and inflammatory bowel disease.

In conclusion, LY96 is a protein that has been shown to be involved in a variety of physiological processes in the body. Its potential as a drug target and biomarker for a variety of diseases makes it an attractive target for further research and development. As the field of immunology continues to evolve, it is likely that the full potential of LY96 will be realized in the coming years.

Protein Name: Lymphocyte Antigen 96

Functions: Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria (PubMed:11160242, PubMed:11593030). Enhances TLR4-dependent activation of NF-kappa-B (PubMed:10359581). Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS (PubMed:10359581)

More Common Targets